Skip to main content
. Author manuscript; available in PMC: 2023 Apr 22.
Published in final edited form as: Nat Med. 2023 Mar 13;29(4):906–916. doi: 10.1038/s41591-023-02234-6

Extended Data Figure 1. Effects of antibiotic exposure on survival outcomes and on development of toxicities in CD19-targeted CAR-T cell treated lymphoma patients.

Extended Data Figure 1.

(A) Kaplan-Meier curves for progression-free survival (PFS) in the German and US cohorts displayed separately according to exposure to any antibiotic within 3 weeks before CAR-T cell infusion. (B) Incidence of progression and (C) overall survival in the combined cohort stratified by pre-infusion antibiotic exposure. (D) PFS for the US and the German patient cohorts displayed according to antibiotic risk strata (no antibiotic exposure vs. exposures to low- or to high-risk antibiotics in the three-weeks pre-infusion time window). (E) Histograms of the frequencies of CRS or ICANS grades according to antibiotic risk stratification; statistics by logrank tests (for survival analyses) and Fisher’s exact tests.